go-v.orgdoi

Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study

Jian Zhang, Zhonghua Zou, Jie Tan, Jianping Shi, Hui Yang, Hao Wang, Jundong Zhou, Jing Xue · Journal of Cancer · 2023

  • DOI 10.7150/jca.83719
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2023

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2023

Abstract

Background and Objective: Immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors may have synergistic effects in elderly patients with advanced driver-negative NSCLC, but its true efficacy remains unclear.In addition, chemotherapy tolerance in elderly NSCLC patients is poor, and the precise identification of the population that may benefit from ICIs combined with angiogenesis inhibitors is also the focus of current research.Methods: We retrospectively compared the efficacy and safety of ICIs combined with or without antiangiogenic agents in elderly patients with advanced driver-gene negative NSCLC ≥65 years of age in the Cancer Center of Suzhou Hospital Affiliated to Nanjing Medical University.The primary endpoint was PFS.Secondary endpoints were OS, ORR, and immune-related adverse events (irAEs).Results: A total of 36 patients in the IA group (immune checkpoint inhibitors plus angiogenesis inhibitors group) and 43 patients in the NIA group (immune checkpoint inhibitors without angiogenesis inhibitors group) were enrolled in the study between January 1, 2019 and December 31, 2021.The median follow-up time for patients in the IA group and NIA group was 18.2 months (95%CI: 14 -22.5 months) and 21.4 months (95%CI: 16.7 -26.1 months), respectively.The median PFS and median OS were longer in the IA group compared to the NIA group (8.1 months vs 5.3 months; HR for PFS: 0.778, 95%CI: 0.474-1.276,P=0.32; NA vs 30.9 months; HR for OS: 0.795, 95%CI: 0.396-1.595,P=0.519).There were no significant differences in median PFS and median OS between the two groups.Subgroup analysis showed that patients in the IA group had significantly longer PFS in the subgroup with PD-L1 expression ≥50% (P=0.017), and the association between different groups and disease progression was still different in the two subgroups (P for interaction = 0.002).There was no significant difference in ORR between the two groups (23.3% vs 30.5%,P=0.465).The incidence of irAEs in the IA group was lower than that in the NIA group (39.5% vs 19.4%, P=0.05), and the cumulative incidence of treatment interruptions due to irAEs was significantly reduced (P=0.045).Conclusion: In elderly patients with advanced driver-negative NSCLC, the addition of antiangiogenic agents to ICIs therapy did not provide significant clinical benefit, but the incidence of irAEs and treatment Ivyspring International

Open the resolved locator · 10.7150/jca.83719

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 12:21 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v14p1623.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.